Abstract: Provided is a method for constructing a gE protein-deleted pseudorabies virus (PRV) strain using an adenine base editor (ABE) and use thereof. The method includes: designing an sgRNA sequence using the ABE with a start codon of the gE gene in a PRV as a target site, ligating an enzyme-digested fragment to a double-stranded DNA fragment with sticky ends to obtain a ligation product; and transforming the ligation product into a competent cell to allow plate screening and culture, selecting a resulting positive bacterial strain to allow expanded culture, and extracting a plasmid from a resulting positive bacterial solution; and transferring the plasmid into a target cell to allow the transfection for 24 h, collecting a resulting virus liquid, and centrifuging the virus liquid to collect a resulting supernatant.

Abstract: The present disclosure relates to the field of biomedicine, and in particular, to an improved mutant of a respiratory syncytial virus (RSV) fusion (F) protein and uses thereof. The mutant can form a trimeric structure without introducing a heterologous trimerization domain. Meanwhile, through mutation designs such as releasing internal electrostatic repulsion, deleting the furin cleavage site, truncating the C-terminal domain, and introducing interchain disulfide bonds, the protein is stabilized in the pre-fusion conformation and exhibits enhanced stability. The mutant in the present disclosure is highly immunogenic when used as a vaccine or a vaccine component and can induce the production of a high level of neutralizing antibodies in the immunized animal, which can be used in the preparation of a vaccine for the prevention or treatment of RSV infection, and can also be used as a reagent for the detection of RSV.

Abstract: Described herein is a method that generally includes infecting a host cell with a rescue adenovirus, wherein the rescue adenovirus genome comprises a loxP site and encodes at least one marker, and wherein the host cell comprises a library of polynucleotides that complement the adenovirus genome marker and encode a detectable polypeptide; incubating the infected host cell under conditions effective to permit recombination between the adenovirus genome and one or more of the library polynucleotides and the production of recombinant adenovirus particles comprising at least on detectable polypeptide; and detecting the at least one detectable polypeptide. Also described are adenovirus libraries constructed using such a method.

Abstract: Nucleic acid molecules and compositions comprising one or more nucleic acid sequences that encode a consensus Crimean-Congo hemorrhagic fever virus (CCHFV) antigens. Immunomodulatory methods and methods of inducing an immune response against CCHFV are disclosed. CCHFV glycoprotein immunogens are disclosed.

Abstract: Provided are establishment and suspension acclimation of a Crandell Reese Feline Kidney (CRFK) adherent cell line, and its application. The CRFK cell line, named CRFK-BLA, is deposited at the China General Microbiological Culture Collection Center (CGMCC), with the address being Institute of Microbiology, Chinese Academy of Sciences, No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing, the deposit number being CGMCC NO: 45703; the CRFK cell line was classified and named CRFK cells, and was deposited on Aug. 17, 2023. A serum-free complete suspension culture type CRFK cell line obtained by acclimation on the basis of CRFK-BLA is named CRFK-BLS, and is deposited at the China General Microbiological Culture Collection Center (CGMCC), with the address being Institute of Microbiology, Chinese Academy of Sciences, No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing, the deposit number being CGMCC NO: 45704; the CRFK cell line was classified and named CRFK suspension cells.

Abstract: Provided is an oncolytic virus expressing a PD-1 binding protein, i.e., an oncolytic adenovirus comprising a fusion protein expressing a PD-1 single-chain antibody, wherein the fusion protein has a structure of S-VL-L-VH-Fc, S is an optional signal peptide sequence, VL is the light chain variable region of the PD-1 single-chain antibody, L is a flexible linker, VH is the heavy chain variable region of the PD-1 single-chain antibody and Fc is an immunoglobulin Fc fragment.

Abstract: A virus lysis and nucleic acid preservation solution is disclosed, including the following components: isopropanol or ethyl alcohol, guanidinium chloride, tri (hydroxymethyl) aminomethane hydrochloride, and ethylenediaminetetraacetic acid. Furthermore, a kit including the virus lysis and nucleic acid preservation solution, a method for preserving viral nucleic acid, and a method for extracting a viral nucleic acid are also provided. The virus lysis and nucleic acid preservation solution of the present invention has the functions of lysing virus and preserving nucleic acid in the lysed virus samples, and it is compatible with lysis buffers, wash buffers, elution buffers, etc. in all kinds of viral nucleic acid extraction kit commonly available in the market.

Abstract: Generation of monoclonal antibodies, or fragments thereof, that recognize the human parainfluenza virus (human PIV) chimeric protein L, where the monoclonal antibodies or fragments thereof have a heavy chain variable region and a light chain variable region. In addition, a method of diagnosing human PIV infection in a biological sample of nasopharyngeal secretion is provided, using the monoclonal antibodies in diagnostic kit format.

Abstract: Generation of monoclonal antibodies, or fragments thereof, that recognize the PB2 protein of the human influenza A virus (Flu), where the monoclonal antibodies or fragments thereof, has a heavy chain variable region and light chain variable region. Furthermore, a diagnostic method is provided to detect Flu infections in biological samples of nasopharyngeal secretions, using monoclonal antibodies in diagnostic kit format.

Abstract: Disclosed is a replication-defective Ad35-vectored immunogenic composition for inducing immune response against SARS COV-2, comprising an Ad35 vector, wherein the Ad35 vector encodes the optimized nucleic acid sequence of SEQ ID NO: 1. Some embodiments of the present disclosure have better safety and use convenience. Experiments have shown that the immunogenic composition can produce more S proteins in human cells. Some embodiments of the present disclosure may be used in combination with another immunogenic composition or may also be used as a therapeutic immunogenic composition for Corona Virus Disease 2019. When a patient is immunized with the Ad35-vectored immunogenic composition of the present disclosure at the initial stage of infection, the immunogenic composition induces an immune response in the human body, thereby achieving a therapeutic effect.

Abstract: The invention relates to the field of veterinary medicine. The invention provides an immunogenic composition, comprising a hemagglutinin protein of avian influenza virus H5 subtype. Also provided is a method of differentiating animals naturally infected with AIV from animals vaccinated with the immunogenic composition of the invention. The immunogenic composition of the invention can provide a broader, more effective, long-lasting and early onset protection on poultry.